Brief: Astellas And Pfizer's Xtandi™ (Enzalutamide) Shows Long-Term Overall Survival In Metastatic Hormone-Sensitive Prostate Cancer
22/05/2025 22:58
Astellas Pharma Inc 4503.T: ASTELLAS AND PFIZER'S XTANDI™ (ENZALUTAMIDE) SHOWS LONG-TERM OVERALL SURVIVAL IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER PFIZER INC - XTANDI PLUS ADT REDUCES RISK OF DEATH BY 30% PFIZER INC - XTANDI PLUS ADT SHOWS 66% FIVE-YEAR SURVIVAL PROBABILITY PFIZER INC - NO NEW SAFETY SIGNALS IDENTIFIED IN FIVE-YEAR FOLLOW-UP Source text: ID:nPn7lLMQra Further company coverage: 4503.T
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)